Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics reported another year of heavy investment in R&D while advancing its precision oncology pipeline. For 2025, the company posted a net loss of $276.5 million, an improvement from $337.7 million in 2024, as research and development expenses fell to $261.4 million from $319.1 million after streamlining programs and transferring FGFR2 asset lirafugratinib to Elevar Therapeutics.
License and other revenue reached $15.4 million, mainly from Elevar milestones, while cash, cash equivalents and investments totaled $554.5 million at year-end. Management believes this liquidity can fund operations into 2029, reducing near-term financing pressure.
Relay’s lead candidate zovegalisib, an allosteric, pan‑mutant, isoform‑selective PI3Kα inhibitor, is in a global Phase 3 breast cancer trial (ReDiscover‑2) and a Phase 1/2 vascular anomalies study. In February 2026, the FDA granted Breakthrough Therapy designation for zovegalisib plus fulvestrant in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer, highlighting the program’s regulatory momentum.
Relay Therapeutics reported narrower losses for 2025 and highlighted key 2026 clinical milestones. Cash, cash equivalents and investments were $554.5 million as of December 31, 2025, compared with $781.3 million a year earlier, and the company expects this cash to fund operations into 2029.
Revenue was $7.0 million in Q4 2025 and $15.4 million for the full year, up from $0 and $10.0 million in 2024, driven by its Elevar license. Research and development expenses fell to $261.4 million for 2025 from $319.1 million, while general and administrative expenses declined to $56.7 million from $76.6 million.
Net loss improved to $54.9 million in Q4 2025, or $0.32 per share, and $276.5 million for the year, or $1.61 per share, versus $76.0 million and $337.7 million in 2024. The company is entering a “pivotal period” in 2026, with initial Phase 1 data for zovegalisib in PIK3CA‑driven vascular anomalies expected in the first half of the year, breast cancer triplet data and frontline Phase 3 plans expected in 2026, and initial Phase 1/2 breast cancer data at the ESMO TAT Congress on March 16, 2026.
Casdin Capital and related entities reported a significant passive stake in Relay Therapeutics, Inc. They disclosed beneficial ownership of 13,003,574 shares of common stock, representing 7.5% of the company. Casdin Partners Master Fund, L.P. directly holds 12,585,000 shares, or 7.3% of the class.
The reporting persons have no sole voting or dispositive power but share voting and dispositive power over these shares. All reported securities are directly owned by advisory clients of Casdin Capital, and the filers certify the holdings are not for the purpose of changing or influencing control of Relay Therapeutics.
Relay Therapeutics, Inc. (RLAY) received an updated Schedule 13G/A showing Casdin-affiliated investors as significant shareholders. Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin each report beneficial ownership of 13,003,574 shares of common stock, representing 7.5% of the class as of 12/31/2025. Casdin Partners Master Fund, L.P. reports 12,585,000 shares, or 7.3% of the class. All reported shares are held by advisory clients of Casdin Capital, and the filers certify the holdings are passive and not intended to change or influence control of Relay Therapeutics.
Relay Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its drug candidate zovegalisib (RLY-2608) in combination with fulvestrant. This designation covers adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer that has recurred or progressed after treatment with a CDK4/6 inhibitor.
Relay Therapeutics President of R&D Donald A. Bergstrom reported automatic sales of common stock to cover tax withholding on recently vested RSUs. On January 27, 2026, 18,895 shares were sold at $7.62 per share, and on January 28, 2026, 2,686 shares were sold at $8.45 per share.
The footnotes state these transactions were executed without his discretion under company policies when 59,550 and 9,072 RSUs vested. After these transactions, he beneficially owned 420,047 shares, including 20,049 shares underlying RSUs.
Relay Therapeutics officer reports ESPP purchase and tax sales. Chief Corporate Development Officer Peter Rahmer bought 994 shares of Relay Therapeutics common stock on December 31, 2025 under the 2020 Employee Stock Purchase Plan at $2.99 per share, a transaction the company notes is voluntarily reported.
On January 27, 2026 he sold 11,684 shares at $7.62 per share, and on January 28, 2026 he sold 1,354 shares at $8.45 per share. Footnotes state both sales were made only to cover income tax withholding on vesting RSUs, with no discretion over the sales. After these transactions, he beneficially owned 276,610 shares, including shares underlying RSUs.
Relay Therapeutics Chief Financial Officer Thomas Catinazzo reported automatic share sales tied to restricted stock unit (RSU) vesting. On January 27, 2026, he sold 13,820 shares of common stock at $7.62 per share, and on January 28, 2026, he sold 1,695 shares at $8.45 per share.
Footnotes state both transactions were sales of shares to cover income tax withholding obligations upon the vesting of 42,394 and 5,724 RSUs, and that he had no discretion over the sales under company policies. After these transactions, he beneficially owned 250,996 and then 249,301 shares, including shares underlying RSUs.
Relay Therapeutics, Inc. reported that Donald A. Bergstrom, its President of R&D, received a grant of stock options on January 13, 2026. The award covers 575,000 stock options, each representing the right to buy one share of common stock at an exercise price of $7.94 per share. Following this grant, Bergstrom beneficially owns 575,000 derivative securities directly.
The options are designed to vest over time. According to the disclosure, the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, and each vesting date requires Bergstrom to continue his service with the company. This structure aligns the award with ongoing tenure and performance in his executive role.
Relay Therapeutics, Inc. reported an insider equity award for Chief Corporate Development Officer Peter Rahmer. On January 13, 2026, he received a stock option covering 475,000 shares of common stock at an exercise price of $7.94 per share.
According to the filing, the shares underlying this option vest in sixteen equal quarterly installments after January 13, 2026, contingent on his continued service with the company through each vesting date. Following this grant, Rahmer beneficially owned 475,000 derivative securities directly in the form of this stock option.